164 related articles for article (PubMed ID: 37674118)
1. Reduced expression of phosphorylated ataxia-telangiectasia mutated gene is related to poor prognosis and gemcitabine chemoresistance in pancreatic cancer.
Xun J; Ohtsuka H; Hirose K; Douchi D; Nakayama S; Ishida M; Miura T; Ariake K; Mizuma M; Nakagawa K; Morikawa T; Furukawa T; Unno M
BMC Cancer; 2023 Sep; 23(1):835. PubMed ID: 37674118
[TBL] [Abstract][Full Text] [Related]
2. CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer.
Zhou Y; Zheng M; Liu Z; Yang H; Zhu P; Jiang JL; Tang J; Chen ZN
Biochem Biophys Res Commun; 2020 Jul; 528(1):62-70. PubMed ID: 32456796
[TBL] [Abstract][Full Text] [Related]
3. PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.
Ono H; Basson MD; Ito H
Mol Cancer Res; 2015 Aug; 13(8):1174-84. PubMed ID: 26013168
[TBL] [Abstract][Full Text] [Related]
4. Anacardic acid inhibits pancreatic cancer cell growth, and potentiates chemotherapeutic effect by Chmp1A - ATM - p53 signaling pathway.
Park M; Upton D; Blackmon M; Dixon V; Craver S; Neal D; Perkins D
BMC Complement Altern Med; 2018 Feb; 18(1):71. PubMed ID: 29463243
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes.
Shi X; Liu S; Kleeff J; Friess H; Büchler MW
Oncology; 2002; 62(4):354-62. PubMed ID: 12138244
[TBL] [Abstract][Full Text] [Related]
6. ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy.
Kim H; Kim ST; Yoo KH; Hong JY; Park YS; Lim HY; Park JO
In Vivo; 2021; 35(1):499-505. PubMed ID: 33402502
[TBL] [Abstract][Full Text] [Related]
7. Ataxia-Telangiectasia-Mutated Protein Expression as a Prognostic Marker in Adenoid Cystic Carcinoma of the Salivary Glands.
Bazarsad S; Kim JY; Zhang X; Kim KY; Lee DY; Ryu MH; Kim J
Yonsei Med J; 2018 Aug; 59(6):717-726. PubMed ID: 29978608
[TBL] [Abstract][Full Text] [Related]
8. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
9. Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis.
Kim H; Saka B; Knight S; Borges M; Childs E; Klein A; Wolfgang C; Herman J; Adsay VN; Hruban RH; Goggins M
Clin Cancer Res; 2014 Apr; 20(7):1865-72. PubMed ID: 24486587
[TBL] [Abstract][Full Text] [Related]
10. Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Yang D; Shi J; Fu H; Wei Z; Xu J; Hu Z; Zhang Y; Yan R; Cai Q
Tumour Biol; 2016 Sep; 37(9):12315-12327. PubMed ID: 27289231
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Wei L; Wen JY; Chen J; Ma XK; Wu DH; Chen ZH; Huang JL
World J Gastroenterol; 2019 Oct; 25(37):5590-5603. PubMed ID: 31602160
[TBL] [Abstract][Full Text] [Related]
12. Ataxia-Telangiectasia and RAD3-Related and Ataxia-Telangiectasia-Mutated Proteins in Epithelial Ovarian Carcinoma: Their Expression and Clinical Significance.
Lee B; Lee HJ; Cho HY; Suh DH; Kim K; No JH; Kim H; Kim YB
Anticancer Res; 2015 Jul; 35(7):3909-16. PubMed ID: 26124337
[TBL] [Abstract][Full Text] [Related]
13. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Xiong G; Liu C; Yang G; Feng M; Xu J; Zhao F; You L; Zhou L; Zheng L; Hu Y; Wang X; Zhang T; Zhao Y
J Hematol Oncol; 2019 Sep; 12(1):97. PubMed ID: 31514732
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells.
He X; Wang J; Wei W; Shi M; Xin B; Zhang T; Shen X
Cancer Biol Ther; 2016; 17(2):188-98. PubMed ID: 26785721
[TBL] [Abstract][Full Text] [Related]
15. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Liu S; Ge Y; Wang T; Edwards H; Ren Q; Jiang Y; Quan C; Wang G
Oncol Rep; 2017 Jun; 37(6):3377-3386. PubMed ID: 28440428
[TBL] [Abstract][Full Text] [Related]
17. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival.
Kamphues C; Bova R; Bahra M; Klauschen F; Muckenhuber A; Sinn BV; Warth A; Goeppert B; Endris V; Neuhaus P; Weichert W; Stenzinger A
Pancreas; 2015 Mar; 44(2):296-301. PubMed ID: 25423555
[TBL] [Abstract][Full Text] [Related]
18. Loss of ataxia-telangiectasia-mutated protein expression correlates with poor prognosis but benefits from anthracycline-containing adjuvant chemotherapy in breast cancer.
Suh KJ; Ryu HS; Lee KH; Kim H; Min A; Kim TY; Yang Y; Moon HG; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA
Breast Cancer Res Treat; 2016 Jul; 158(2):233-41. PubMed ID: 27329169
[TBL] [Abstract][Full Text] [Related]
19. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
[TBL] [Abstract][Full Text] [Related]
20. ATM-Mutated Pancreatic Cancer: Clinical and Molecular Response to Gemcitabine/Nab-Paclitaxel After Genome-Based Therapy Resistance.
Martino C; Pandya D; Lee R; Levy G; Lo T; Lobo S; Frank RC
Pancreas; 2020 Jan; 49(1):143-147. PubMed ID: 31856090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
